Development and validation of a prediction model for the risk of developing febrile neutropenia in the first cycle of chemotherapy among elderly patients with breast, lung, colorectal, and prostate cancer.
Development and validation of a prediction model for the risk of developing febrile neutropenia in the first cycle of chemotherapy among elderly patients with breast, lung, colorectal, and prostate cancer.
复制标题
在乳腺癌，肺，结直肠癌和前列腺癌的老年患者中，在化学疗法的第一个化学疗法周期中发展和验证的预测模型的发展和验证。
DOI：
10.1007/s00520-010-0821-1
复制
发表时间：
2011-03
影响因子：
3.1
通讯作者：
Wong, Mitchell
中科院分区：
文献类型：
--
作者：
Hosmer, Wylie;Malin, Jennifer;Wong, Mitchell
目前的指南建议，当发热性中性粒细胞减少症（FN）的风险大于20%时，预防性使用粒细胞集落刺激因子（G-CSF）。高龄是FN的一个危险因素;然而，对老年人群中其他因素对FN发病率的影响知之甚少。我们分析了SEER-医疗保险数据（1994-2005），以开发和验证乳腺癌、结直肠癌、前列腺癌和肺癌患者化疗开始后因发热、感染或中性粒细胞减少而住院的预测模型。在多变量分析中（N = 58，053）FN的独立预测因素包括诊断时的晚期[2期（OR 1.29; 95% CI：1.09-1.53），3期（1.38; 95% CI：1.19-1.60）和4期（1.57; 95% CI：1.35-1.83）]，相关共病的数量[1种疾病（1.13; 95% CI：1.02-1.28），两种条件（1.39; 95% CI：1.22-1.57），以及三种或三种以上条件（1.81; 95% CI：1.61-2.04）]，接受骨髓抑制化疗（1.11; 95% CI：0.94-1.32），在诊断后1个月内接受化疗[1 - 3个月（0.70; 95% CI：0.62-0.80）和3个月以上（0.63; 95% CI：0.55-0.73）]。我们建立了一个预测模型，发热性中性粒细胞减少症的第一个周期的化疗在一个大的人口老年常见恶性肿瘤患者。
Current guidelines recommend prophylactic use of granulocyte-colony stimulating factors (G-CSF) when febrile neutropenia (FN) risk is greater than 20%. Advanced age is a risk factor for FN; however, little is known about the impact of other factors on the incidence of FN in an older population. We analyzed SEER-Medicare data (1994–2005) to develop and validate a prediction model for hospitalization with fever, infection, or neutropenia occurring after chemotherapy initiation for patients with breast, colorectal, prostate, and lung cancer. In multivariate analysis (N = 58,053) independent predictors of FN included advanced stage at diagnosis [stage 2 (OR 1.29; 95% CI: 1.09–1.53), stage 3 (1.38; 95% CI: 1.19–1.60), and stage 4 (1.57; 95% CI: 1.35–1.83)], number of associated comorbid conditions [one condition (1.13; 95% CI: 1.02–1.28), two conditions (1.39; 95% CI: 1.22–1.57), and three or more conditions (1.81; 95% CI: 1.61–2.04)], receipt of myelosuppressive chemotherapy (1.11; 95% CI: 0.94–1.32), and receipt of chemotherapy within 1 month of diagnosis [1 to 3 months (0.70; 95% CI: 0.62–0.80) and greater than 3 months (0.63; 95% CI: 0.55–0.73)]. We created a prediction model for febrile neutropenia with first cycle of chemotherapy in a large population of elderly patients with common malignancies.
登录
查看更多内容
影响因子：
8.8
作者：
通讯作者：
--
影响因子：
7.2
作者：
DEYO, RA;CHERKIN, DC;CIOL, MA
通讯作者：
CIOL, MA
影响因子：
7.2
作者：
Klabunde, CN;Potosky, AL;Warren, JL
通讯作者：
Warren, JL
影响因子：
--
作者：
Newschaffer, CJ;Penberthy, L;Whittemore, M
通讯作者：
Whittemore, M
影响因子：
5.8
作者：
Lyman, GH;Lyman, CH;Agboola, O
通讯作者：
Agboola, O